- Strategic and Tactical Capabilities to Ensure Audience Engagement
- Healthcare Public Relations Veteran Dr. Matt Middleman Appointed to Lead LifeSci Public Relations
- Unique Synergies Realized by Integrating LifeSci’s PR and IR Capabilities
NEW YORK, Feb. 10, 2017 -- LifeSci Partners today announced the launch of LifeSci Public Relations, a fully integrated corporate communications and public relations firm with a broad array of capabilities aimed at building relationships and encouraging engagement by all corporate audiences. Dr. Matt Middleman, who has almost two decades of experience in healthcare communications, equity analysis, clinical medicine and basic science, will head LifeSci Public Relations. The team of professionals has successfully planned and implemented public relations programs for small-, medium- and large-sized public and private healthcare companies. LifeSci Public Relations’ offering will integrate with that of LifeSci’s broader investor relations and capital markets offerings, providing significant communications synergy and value to the firm’s clients.
The LifeSci Public Relations team has scientific and medical expertise and deep and longstanding relationships with editors and journalists from key industry, trade and financial media outlets that will be leveraged when executing successful public relations campaigns. Dr. Middleman and his team have substantial experience in multiple clinical and technological fields, including oncology, cardiovascular disease, immunology, orphan diseases, RNAi, gene therapy, biologics, antibody-drug conjugates, diagnostics, medical technology/devices and healthcare services.
Andrew McDonald, Ph.D., co-founder of LifeSci Partners, said, “We are launching LifeSci Public Relations to address our clients’ needs across the entire spectrum of corporate communications. This fully-integrated offering blends our existing investor relations activities with those of the new public relations program. Our clients will see an enormous amount of synergy. We now offer a level of domain expertise in both healthcare IR and PR that is unique among our peers. LifeSci is committed to helping our healthcare clients achieve their corporate goals of developing and marketing new products and technologies, by building awareness with all key stakeholders, including the media, investment and medical communities.”
Matt Middleman, M.D., managing director and head of LifeSci Public Relations, added, “I look forward to the opportunity of leading LifeSci Public Relations and providing our clients with an exceptional level of strategic communications counsel and media relations execution that aligns with their corporate goals. I am particularly proud to be launching this endeavor within LifeSci Partners, a firm with an impressive track record of providing its clients with the highest quality service.”
Each LifeSci Public Relations communications program will be specifically tailored to meet the needs of each individual client. We will build corporate, clinical, product and disease awareness by fostering relationships with prominent influencers in each of those industry segments.
Dr. Middleman joins LifeSci Public Relations from Russo Partners where he was vice president and responsible for planning and overseeing numerous successful communications programs. Before joining Russo Partners, he held an assistant professorship at the Albert Einstein College of Medicine and a faculty position at the Montefiore Medical Center specializing in transplant anesthesiology. Dr. Middleman also spent time as a biotechnology equity analyst for an independent research firm. Prior to this, he trained and taught at top institutions with many years of clinical experience practicing in multiple fields, including surgery and anesthesiology, as well as conducting research in immunology and oncology at the NIH and Mount Sinai. Dr. Middleman holds a bachelor’s degree in biological sciences from Cornell University and received his medical degree from the Icahn School of Medicine at Mount Sinai. He has authored numerous peer-reviewed publications.
About LifeSci Public Relations
LifeSci Public Relations is a fully independent division of LifeSci Partners. The firm is uniquely capable of helping clients engage with their corporate audiences and achieve their business objectives by communicating through the media and utilizing a broad array of social and digital media tools. The highly-experienced team has a track record of successfully planning and implementing fully integrated public relations programs for small-, medium- and large-sized public and private healthcare companies in multiple clinical and technological fields.
For more information please visit our website at www.lifescipublicrelations.com.
Contacts Matt Middleman, M.D. LifeSci Public Relations Phone: 646-627-8384 [email protected] Andrew McDonald, Ph.D. LifeSci Advisors, LLC Phone: 646-597-6987 [email protected] Michael Rice LifeSci Advisors, LLC Phone: 646-597-6979 [email protected]


Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
OpenAI Addresses Security Vulnerability in macOS App Certification Process
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Chinese Cars in Europe: Consumer Trust Is Shifting Fast
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 



